Crystal Blockchain: Peer-to-Peer Exchanges Need Regulation to Lower Money Laundering Risk
At the V20 Summit in November 2020, the Financial Action Task Force (FATF) announced that regulatory requirements for peer-to-peer (P2P) exchanges – along the lines of those for Virtual Asset Service Providers (VASPs) – will likely emerge in 2021 to combat money laundering (ML). The FATF is now collecting data on these exchanges to allow their guidelines to reflect P2Ps.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210203005351/en/
Volumes (in BTC and USD) sent to and received by P2P Exchanges 2019-2020 (Graphic: Business Wire)
The Crystal team did a YoY analysis of P2P transaction activity to see whether the FATF's intentions to bring tighter regulations has affected the amount of bitcoin transferred via these decentralized exchanges from January 2019 to December 2020.
Key Findings:
- Sent and received amounts (in US dollar) by P2P exchanges in December 2020 increased by +164% and +197% compared to January 2019.
- Received and sent amounts (in bitcoin) in December 2020 decreased by -55% and -50%, compared with January 2019.
- The main reason for the disparity is that while the price of bitcoin has grown 6X between January 2019 and December 2020, the popularity of P2P exchanges has declined.
- The amounts sent and received in bitcoin by P2P exchanges rapidly dropped in November and December 2020, and this is most likely due to the November 2020 FATF announcement of future regulation of P2P.
- The amounts of received bitcoin by Non-P2P exchanges have had a growing trend in comparison to P2P exchanges, explained by higher popularity and a better “reputation”.
P2P exchanges may be less popular than Non-P2P thus far for a few reasons:
- less regulatory oversight from the FATF,
- more complicated operational principles,
- they might be considered potential ML platforms due to a lack of intermediaries.
That being said, innovation and developments in the P2P sector continue to rise, and as regulatory requirements increase, P2P will become a safer and more transparent space.
Compliance software for P2P transactions is being developed, and the P2P exchange sector will increase in popularity when it's possible to further manage AML and compliance risk.
Visit the Crystal website to see the full Report on P2P Transaction Volumes 2019-2020.
About Crystal Blockchain:
Crystal is the all-in-one blockchain analytics tool for crypto AML compliance. Available as a free demo version, SaaS, API, and for on-premise installation. Engineered by the Bitfury Group.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210203005351/en/
Contact information
Oleh Rozvadovskyy
+38-050-377-04-87
oleh.rozvadovskyy@crystalblockchain.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom